Trade Gritstone bio, Inc. - GRTS CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.0190 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Gritstone bio Inc ESG Risk Ratings
High Medium Low Negligible
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Key Stats
| Prev. Close* | 1.2755 |
| Open* | 1.2955 |
| 1-Year Change* | -55.44% |
| Day's Range* | 1.2755 - 1.5255 |
| 52 wk Range | 1.14-4.05 |
| Average Volume (10 days) | 1.38M |
| Average Volume (3 months) | 49.05M |
| Market Cap | 122.04M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 95.34M |
| Revenue | 10.23M |
| EPS | -1.55 |
| Dividend (Yield %) | N/A |
| Beta | 0.44 |
| Next Earnings Date | Mar 7, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 1, 2023 | 1.5255 | 0.2200 | 16.85% | 1.3055 | 1.5355 | 1.2755 |
| Nov 30, 2023 | 1.2755 | -0.0400 | -3.04% | 1.3155 | 1.3655 | 1.2755 |
| Nov 29, 2023 | 1.3055 | 0.0000 | 0.00% | 1.3055 | 1.3455 | 1.2755 |
| Nov 28, 2023 | 1.2955 | -0.0300 | -2.26% | 1.3255 | 1.3655 | 1.2855 |
| Nov 27, 2023 | 1.3555 | 0.0200 | 1.50% | 1.3355 | 1.3555 | 1.2655 |
| Nov 24, 2023 | 1.3555 | 0.0400 | 3.04% | 1.3155 | 1.3855 | 1.2855 |
| Nov 22, 2023 | 1.3055 | 0.0400 | 3.16% | 1.2655 | 1.3255 | 1.2655 |
| Nov 21, 2023 | 1.2655 | -0.0600 | -4.53% | 1.3255 | 1.3255 | 1.2555 |
| Nov 20, 2023 | 1.3155 | -0.0400 | -2.95% | 1.3555 | 1.3855 | 1.3155 |
| Nov 17, 2023 | 1.3555 | 0.0000 | 0.00% | 1.3555 | 1.3955 | 1.2955 |
| Nov 16, 2023 | 1.3555 | -0.0500 | -3.56% | 1.4055 | 1.4655 | 1.3155 |
| Nov 15, 2023 | 1.4355 | 0.0700 | 5.13% | 1.3655 | 1.4955 | 1.3455 |
| Nov 14, 2023 | 1.3555 | -0.0600 | -4.24% | 1.4155 | 1.4755 | 1.3455 |
| Nov 13, 2023 | 1.3755 | -0.0500 | -3.51% | 1.4255 | 1.4555 | 1.3455 |
| Nov 10, 2023 | 1.4155 | -0.1400 | -9.00% | 1.5555 | 1.5655 | 1.4055 |
| Nov 9, 2023 | 1.5555 | -0.1300 | -7.71% | 1.6855 | 1.6855 | 1.5155 |
| Nov 8, 2023 | 1.6755 | -0.1200 | -6.68% | 1.7955 | 1.7955 | 1.6555 |
| Nov 7, 2023 | 1.8155 | 0.0100 | 0.55% | 1.8055 | 1.8455 | 1.7955 |
| Nov 6, 2023 | 1.8255 | -0.0500 | -2.67% | 1.8755 | 1.9055 | 1.7955 |
| Nov 3, 2023 | 1.8755 | 0.0300 | 1.63% | 1.8455 | 1.9555 | 1.8455 |
Gritstone bio, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Tuesday, December 5, 2023 | ||
| Time (UTC) 16:00 | Country US
| Event Gritstone bio Inc at Goldman Sachs Catalyst Clinic (Virtual) Gritstone bio Inc at Goldman Sachs Catalyst Clinic (Virtual)Forecast -Previous - |
| Thursday, March 7, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q4 2023 Gritstone bio Inc Earnings Release Q4 2023 Gritstone bio Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 19.945 | 48.214 | 4.037 | 4.365 | 1.187 |
| Total Operating Expense | 140.373 | 123.423 | 110.054 | 102.305 | 66.771 |
| Selling/General/Admin. Expenses, Total | 28.97 | 25.933 | 21.411 | 19.409 | 11.806 |
| Research & Development | 111.403 | 97.49 | 88.643 | 82.896 | 54.965 |
| Operating Income | -120.428 | -75.209 | -106.017 | -97.94 | -65.584 |
| Interest Income (Expense), Net Non-Operating | 0.741 | 0.127 | 0.703 | 3.507 | 0.809 |
| Net Income Before Taxes | -119.687 | -75.082 | -105.314 | -94.433 | -64.775 |
| Net Income After Taxes | -119.687 | -75.082 | -105.314 | -94.433 | -64.775 |
| Net Income Before Extra. Items | -119.687 | -75.082 | -105.314 | -94.433 | -64.775 |
| Net Income | -119.687 | -75.082 | -105.314 | -94.433 | -64.775 |
| Income Available to Common Excl. Extra. Items | -119.687 | -75.082 | -105.314 | -94.433 | -64.775 |
| Income Available to Common Incl. Extra. Items | -119.687 | -75.082 | -105.314 | -94.433 | -64.775 |
| Diluted Net Income | -119.687 | -75.082 | -105.314 | -94.433 | -64.775 |
| Diluted Weighted Average Shares | 90.9183 | 78.8852 | 37.7924 | 33.5548 | 29.1938 |
| Diluted EPS Excluding Extraordinary Items | -1.31642 | -0.95179 | -2.78665 | -2.81429 | -2.21879 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -1.31642 | -0.95179 | -2.78665 | -2.81429 | -2.21879 |
| Revenue | 19.945 | 48.214 | 4.037 | 4.365 | 1.187 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 1.955 | 2.443 | 4.262 | 3.021 | 5.471 |
| Revenue | 1.955 | 2.443 | 4.262 | 3.021 | 5.471 |
| Total Operating Expense | 37.683 | 37.259 | 36.181 | 32.898 | 35.139 |
| Selling/General/Admin. Expenses, Total | 6.716 | 6.745 | 6.761 | 6.462 | 7.792 |
| Research & Development | 30.967 | 30.514 | 29.42 | 26.436 | 27.347 |
| Operating Income | -35.728 | -34.816 | -31.919 | -29.877 | -29.668 |
| Interest Income (Expense), Net Non-Operating | 0.494 | 0.834 | 0.629 | -0.089 | 0.153 |
| Net Income Before Taxes | -35.256 | -33.982 | -31.29 | -29.966 | -29.515 |
| Net Income After Taxes | -35.256 | -33.982 | -31.29 | -29.966 | -29.515 |
| Net Income Before Extra. Items | -35.256 | -33.982 | -31.29 | -29.966 | -29.515 |
| Net Income | -35.256 | -33.982 | -31.29 | -29.966 | -29.515 |
| Income Available to Common Excl. Extra. Items | -35.256 | -33.982 | -31.29 | -29.966 | -29.515 |
| Income Available to Common Incl. Extra. Items | -35.256 | -33.982 | -31.29 | -29.966 | -29.515 |
| Diluted Net Income | -35.256 | -33.982 | -31.29 | -29.966 | -29.515 |
| Diluted Weighted Average Shares | 91.2242 | 87.8484 | 86.8949 | 86.5974 | 86.4486 |
| Diluted EPS Excluding Extraordinary Items | -0.38648 | -0.38683 | -0.36009 | -0.34604 | -0.34142 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.38648 | -0.38683 | -0.36009 | -0.34604 | -0.34142 |
| Other, Net | -0.022 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 182.878 | 220.59 | 175.39 | 131.273 | 157.636 |
| Cash and Short Term Investments | 171.887 | 201.633 | 171.058 | 127.776 | 153.11 |
| Cash & Equivalents | 38.191 | 81.312 | 36.801 | 46.382 | 52.183 |
| Short Term Investments | 116.389 | 108.346 | 1.002 | 70.368 | 100.927 |
| Prepaid Expenses | 6.35 | 4.982 | 3.114 | 2.725 | 4.077 |
| Total Assets | 240.754 | 278.106 | 221.567 | 184.389 | 189.558 |
| Property/Plant/Equipment, Total - Net | 38.816 | 44.542 | 43.449 | 50.338 | 29.494 |
| Property/Plant/Equipment, Total - Gross | 67.598 | 66.818 | 60.374 | 60.648 | 36.245 |
| Accumulated Depreciation, Total | -28.782 | -22.276 | -16.925 | -10.31 | -6.751 |
| Other Long Term Assets, Total | 15.029 | 8.357 | 2.728 | 2.778 | 2.428 |
| Total Current Liabilities | 34.801 | 39.956 | 26.988 | 19.5 | 15.108 |
| Accounts Payable | 8.694 | 4.23 | 9.578 | 4.621 | 4.825 |
| Accrued Expenses | 20.976 | 18.525 | 13.935 | 9.923 | 4.943 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 69.973 | 62.02 | 54.828 | 50.045 | 40.436 |
| Total Long Term Debt | 19.349 | 0 | 0 | 0 | 10.49 |
| Capital Lease Obligations | 0 | 10.49 | |||
| Other Liabilities, Total | 15.823 | 22.064 | 27.84 | 30.545 | 14.838 |
| Total Equity | 170.781 | 216.086 | 166.739 | 134.344 | 149.122 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.022 | 0.02 | 0.018 | 0.017 | 0.016 |
| Additional Paid-In Capital | 691.91 | 617.523 | 493.023 | 355.291 | 275.593 |
| Retained Earnings (Accumulated Deficit) | -521.071 | -401.384 | -326.302 | -220.988 | -126.402 |
| Other Equity, Total | -0.08 | -0.073 | 0 | 0.024 | -0.085 |
| Total Liabilities & Shareholders’ Equity | 240.754 | 278.106 | 221.567 | 184.389 | 189.558 |
| Total Common Shares Outstanding | 86.8949 | 67.9878 | 47.5527 | 36.333 | 28.8231 |
| Other Current Assets, Total | 3.977 | 12.59 | 1.218 | 0.29 | 0.449 |
| Other Current Liabilities, Total | 5.131 | 17.201 | 3.475 | 4.956 | 5.34 |
| Cash | 17.307 | 11.975 | 133.255 | 11.026 | |
| Total Receivables, Net | 0.664 | 1.385 | 0.482 | ||
| Accounts Receivable - Trade, Net | 1.385 | ||||
| Long Term Investments | 4.031 | 4.617 | |||
| Long Term Debt | 19.349 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 90.82 | 122.376 | 154.765 | 182.878 | 153.427 |
| Cash and Short Term Investments | 83.948 | 114.533 | 145.808 | 171.887 | 139.809 |
| Cash & Equivalents | 29.539 | 41.414 | 47.128 | 55.498 | 64.909 |
| Short Term Investments | 54.409 | 73.119 | 98.68 | 116.389 | 74.9 |
| Total Receivables, Net | 0.337 | 0.399 | 0.566 | 0.664 | 0.529 |
| Prepaid Expenses | 4.354 | 4.803 | 6.314 | 6.35 | 6.362 |
| Other Current Assets, Total | 2.181 | 2.641 | 2.077 | 3.977 | 6.727 |
| Total Assets | 187.217 | 222.623 | 209.952 | 240.754 | 205.242 |
| Property/Plant/Equipment, Total - Net | 89.861 | 92.428 | 35.98 | 38.816 | 40.993 |
| Property/Plant/Equipment, Total - Gross | 123.68 | 124.524 | 66.561 | 67.598 | 68.011 |
| Accumulated Depreciation, Total | -33.819 | -32.096 | -30.581 | -28.782 | -27.018 |
| Other Long Term Assets, Total | 6.536 | 7.819 | 19.207 | 15.029 | 10.822 |
| Total Current Liabilities | 23.383 | 22.111 | 24.672 | 34.801 | 32.313 |
| Accounts Payable | 4.265 | 4.925 | 5.975 | 8.694 | 2.885 |
| Accrued Expenses | 17.817 | 14.368 | 15.896 | 20.976 | 20.74 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 1.301 | 2.818 | 2.801 | 5.131 | 8.688 |
| Total Liabilities | 113.235 | 113.056 | 69.074 | 69.973 | 68.395 |
| Total Long Term Debt | 29.868 | 29.723 | 29.576 | 19.349 | 19.281 |
| Other Liabilities, Total | 59.984 | 61.222 | 14.826 | 15.823 | 16.801 |
| Total Equity | 73.982 | 109.567 | 140.878 | 170.781 | 136.847 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.022 | 0.022 | 0.022 | 0.022 | 0.02 |
| Additional Paid-In Capital | 702.755 | 699.979 | 695.961 | 691.91 | 626.889 |
| Retained Earnings (Accumulated Deficit) | -628.743 | -590.309 | -555.053 | -521.071 | -489.781 |
| Other Equity, Total | -0.052 | -0.125 | -0.052 | -0.08 | -0.281 |
| Total Liabilities & Shareholders’ Equity | 187.217 | 222.623 | 209.952 | 240.754 | 205.242 |
| Total Common Shares Outstanding | 93.0754 | 91.2242 | 87.8484 | 86.8949 | 73.134 |
| Long Term Investments | 0 | 0 | 0 | 4.031 | 0 |
| Accounts Receivable - Trade, Net | 0 | ||||
| Long Term Debt | 29.868 | 29.723 | 29.576 | 19.349 | 19.281 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -119.687 | -75.082 | -105.314 | -94.433 | -64.775 |
| Cash From Operating Activities | -115.946 | -50.678 | -89.102 | -85.011 | -38.162 |
| Cash From Operating Activities | 6.56 | 6.347 | 6.644 | 4.745 | 3.961 |
| Non-Cash Items | 21.708 | 19.421 | 14.499 | 10.332 | 2.443 |
| Changes in Working Capital | -24.527 | -1.364 | -4.931 | -5.655 | 20.209 |
| Cash From Investing Activities | -12.964 | -118.553 | 65.949 | 15.841 | -59.103 |
| Capital Expenditures | -5.872 | -5.463 | -3.515 | -16.173 | -5.663 |
| Other Investing Cash Flow Items, Total | -7.092 | -113.09 | 69.464 | 32.014 | -53.44 |
| Cash From Financing Activities | 83.098 | 108.76 | 135.801 | 74.395 | 110.441 |
| Issuance (Retirement) of Stock, Net | 65.506 | 117.21 | 135.905 | 75.202 | 113.521 |
| Net Change in Cash | -45.812 | -60.471 | 112.648 | 5.225 | 13.176 |
| Financing Cash Flow Items | -1.31 | -8.394 | -0.104 | -0.807 | -3.08 |
| Issuance (Retirement) of Debt, Net | 18.902 | -0.056 | |||
| Cash Interest Paid | 0.647 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -33.982 | -119.687 | -88.397 | -58.431 | -28.916 |
| Cash From Operating Activities | -40.09 | -115.946 | -85.572 | -59.788 | -33.451 |
| Cash From Operating Activities | 1.799 | 6.56 | 4.769 | 3.093 | 1.589 |
| Non-Cash Items | 4.503 | 21.708 | 16.845 | 11.449 | 5.659 |
| Changes in Working Capital | -12.41 | -24.527 | -18.789 | -15.899 | -11.783 |
| Cash From Investing Activities | 21.173 | -12.964 | 33.188 | 30.113 | 7.634 |
| Capital Expenditures | -1.567 | -5.872 | -4.389 | -3.265 | -1.812 |
| Other Investing Cash Flow Items, Total | 22.74 | -7.092 | 37.577 | 33.378 | 9.446 |
| Cash From Financing Activities | 8.647 | 83.098 | 18.733 | -0.607 | -0.917 |
| Financing Cash Flow Items | -3.231 | -1.31 | -1.005 | -0.959 | -0.959 |
| Issuance (Retirement) of Stock, Net | 1.96 | 65.506 | 0.755 | 0.465 | 0.098 |
| Net Change in Cash | -10.27 | -45.812 | -33.651 | -30.282 | -26.734 |
| Issuance (Retirement) of Debt, Net | 9.918 | 18.902 | 18.983 | -0.113 | -0.056 |
| Cash Interest Paid | 0.436 | 0.647 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | Hedge Fund | 8.1371 | 7573680 | -106187 | 2023-06-30 | HIGH |
| Redmile Group, LLC | Investment Advisor/Hedge Fund | 7.3706 | 6860226 | -66700 | 2023-06-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.0574 | 5637975 | 3828281 | 2023-06-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.3502 | 4049002 | 388103 | 2023-06-30 | LOW |
| Versant Ventures | Venture Capital | 3.8261 | 3561150 | 0 | 2023-06-30 | LOW |
| Avidity Partners Management LP | Hedge Fund | 2.9712 | 2765500 | -94471 | 2023-06-30 | HIGH |
| Frazier Healthcare Partners | Venture Capital | 2.5804 | 2401714 | -2760634 | 2023-06-30 | LOW |
| Balyasny Asset Management LP | Hedge Fund | 2.0221 | 1882048 | -490982 | 2023-06-30 | HIGH |
| Morgan Stanley & Co. LLC | Research Firm | 1.878 | 1747998 | -55290 | 2023-06-30 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.8008 | 1676058 | 931478 | 2023-06-30 | LOW |
| Allen (Andrew R) | Individual Investor | 1.6368 | 1523429 | -678717 | 2023-03-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.6249 | 1512337 | 1239007 | 2023-06-30 | LOW |
| Millennium Management LLC | Hedge Fund | 1.3918 | 1295437 | 584219 | 2023-06-30 | HIGH |
| Assenagon Asset Management S.A. | Investment Advisor | 1.3411 | 1248264 | -290104 | 2023-06-30 | HIGH |
| Ensign Peak Advisors, Inc. | Foundation | 0.8572 | 797880 | 677353 | 2023-06-30 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 0.8491 | 790316 | -8197 | 2023-06-30 | LOW |
| Palo Alto Investors LP | Hedge Fund | 0.7157 | 666127 | 0 | 2023-06-30 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.6814 | 634181 | 491876 | 2023-06-30 | LOW |
| Citadel Advisors LLC | Hedge Fund | 0.4731 | 440348 | -117417 | 2023-06-30 | LOW |
| Hawryluk (Matthew Ph.D.) | Individual Investor | 0.4042 | 376207 | 191771 | 2023-02-02 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Gritstone bio, Inc. Company profile
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was founded in 2015 and is headquartered in Emeryville, California.| Industry: | Biopharmaceuticals |
5959 Horton Street, Suite 300
EMERYVILLE
CALIFORNIA 94608
US
Income Statement
- Annual
- Quarterly
News
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com